Last updated on November 2019

PF-06651600 for the Treatment of Alopecia Areata


Brief description of study

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

Clinical Study Identifier: NCT03732807

Find a site near you

Start Over

Mosaic Dermatology

Santa Monica, CA United States
  Connect »

Siperstein Dermatology Group

Boynton Beach, FL United States
  Connect »

Park Avenue Dermatology

Orange Park, FL United States
  Connect »

Denova Research

Chicago, IL United States
  Connect »

Skin Specialists, PC

Omaha, NE United States
  Connect »

The Skin Centre

Benowa, Australia
  Connect »

Sinclair Dermatology

East Melbourne, Australia
  Connect »

York Dermatology Center

Richmond Hill, ON Canada
  Connect »

Research Toronto

Toronto, ON Canada
  Connect »

Yale School of Medicine

New Haven, CT United States
  Connect »

Church Street Research Unit

New Haven, CT United States
  Connect »

Bellevue Hospital Center

New York, NY United States
  Connect »

UNC CTRC

Chapel Hill, NC United States
  Connect »

Kaiser Permanente

San Francisco, CA United States
  Connect »

Northwestern Medical Group

Chicago, IL United States
  Connect »

Northwestern Medicine

Chicago, IL United States
  Connect »

Cleveland Clinic Foundation

Cleveland, OH United States
  Connect »

Emovis GmbH

Berlin, Germany
  Connect »